Jubilant Pharmova assigned IND AA+/Stable to ₹1,400 Cr NCDs.

Jubilant Pharmova Limited (JUBLPHARMA) has received a credit rating assignment from India Ratings and Research Pvt Ltd. The rating is for proposed non-convertible debentures amounting to ₹1,400 crore. The instrument is Proposed Non-Convertible Debentures of ₹1,400 crore. The assigned rating is IND AA+/Stable. The rating action is Assigned. The key trigger is the assignment of an IND AA+/Stable rating for the proposed ₹1,400 crore NCD issuance, which supports the company’s funding plans without equity dilution. This reflects a favourable view of its credit profile in the specialty pharmaceuticals and CDMO space. Peers such as Syngene International, Piramal Pharma, and Divi’s Laboratories may face comparison on balance-sheet strength and debt-raising capacity. Near-term prices could see a mild positive reaction on the rating assignment and funding visibility. Risks include the final terms of the NCD issuance or any subsequent pressure on leverage metrics. Competitors listed: Syngene International, Piramal Pharma, Divi’s Laboratories.